Atlas Trials

A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

Clinical trial NCT00458146 · COMPLETED

Trial details

NCT number
NCT00458146
Sponsor
Merrimack Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Rheumatoid Arthritis
Start date
2007-02-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.